Resmed (RSMDF) Net Equity Issued and Repurchased (2009 - 2026)

Resmed (RSMDF) has reported Net Equity Issued and Repurchased for 18 consecutive years, with $29.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Equity Issued and Repurchased fell 2.79% year-over-year to $29.3 million; the trailing twelve-month figure through Jun 2026 stood at $74.5 million (changed 0.09% YoY), and the FY2026 full-year result was $74.5 million, changed 0.09% from the prior year.
• Net Equity Issued and Repurchased advanced to $29.3 million in Q2 2026 per RSMDF's latest filing, from $7.4 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $30.2 million in Q2 2025 and bottomed at $983000.0 in Q1 2023.
• Historically, Net Equity Issued and Repurchased has averaged $15.3 million across 5 years, with a median of $14.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Net Equity Issued and Repurchased soared 1840.69% in 2022, then sank 65.07% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at $22.1 million in 2022, then retreated by 11.48% to $19.5 million in 2023, then jumped by 37.66% to $26.9 million in 2024, then rose by 9.97% to $29.6 million in 2025, then declined by 0.82% to $29.3 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $29.3 million, $7.4 million, and $29.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.